Vimarsana
Biggest News Aggregation in the World

Page 7 - Global Research Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Global Research Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Global Research Development Today - Breaking & Trending Today

HeidelbergCement announces major changes to Managing Board - Vimarsana News

HeidelbergCement announces major changes to Managing Board

Advertisement In line with HeidelbergCement’s ‘Beyond 2020’ strategic targets, the Supervisory Board of HeidelbergCement has decided to establish two new positions on the Managing Board in order to further drive the company’s major transformation in sustainability and digitalisation. Both changes reflect the company’s ambition to be industry leader on the road to carbon neutrality and become the first industrial technology group in the building materials industry. Dr. Nicola Kimm (51) will take over the newly established Managing Board position as Chief Sustainability Officer of Hei...

TuSimple Announces Executive Advisory Board Consisting of Industry and Regulatory Experts - Vimarsana News

TuSimple Announces Executive Advisory Board Consisting of Industry and Regulatory Experts

TuSimple Announces Executive Advisory Board Consisting of Industry and Regulatory Experts Leaders from Schneider, Werner, U.S. Xpress, Canadian National, and VectoIQ, as well as former U.S. congressmen, join TuSimple's advisory board News provided by Share this article SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- TuSimple, a global self-driving technology company, announced today the members of its newly established Executive Advisory Board including Jeff Denham, Eric Fuller, Steve Girsky, Jim Kolbe, Derek Leathers, Mark Rourke, and Jean-Jacques Ruest. TuSimple's Executive Advisory Board will pr...

LEO Pharma initiates head-to-head study to evaluate brodalumab vs. guselkumab in adult patients with moderate-to-severe psoriasis who have inadequate response to ustekinumab - Vimarsana News

LEO Pharma initiates head-to-head study to evaluate brodalumab vs. guselkumab in adult patients with moderate-to-severe psoriasis who have inadequate response to ustekinumab

Posted on 7466 LEO Pharma A/S – a global leader in medical dermatology – announced today that the first patient has been screened in the first head-to-head clinical trial to evaluate brodalumab (marketed in the European Union as Kyntheum ®) compared with guselkumab (marketed globally as Tremfya ®) in adult patients with moderate-to-severe plaque psoriasis who have an inadequate response to ustekinumab (marketed globally as Stelara ®) treatment. Per Sproegel (Photo: Business Wire) The COBRA (COmparing BRodalumab And guselkuma...